DepYmed, Inc.

DepYmed’s Developmental Compound, DPM-1001, May Lead to a Potential Treatment for Wilson’s Disease

Reported by Researchers at Cold Spring Harbor Laboratory June 29, 2018 (Farmingdale, NY) — DepYmed, Inc. in collaboration with Cold Spring Harbor Laboratory (CSHL), has reported promising preclinical experiments on a compound, DPM-1001, currently being developed by DepYmed, Inc. for the potential treatment of patients with Wilson’s Disease as well as other disorders—including certain types […]
Read More
DepYmed, Inc.

DepYmed, Inc. Announces Appointment of New President and CEO

Andreas G. Grill is appointed President and Chief Executive Officer February 17, 2015 (Cold Spring Harbor, NY) – DepYmed, Inc. is pleased to announce the appointment of Andreas G. Grill as President and Chief Executive Officer. Mr. Grill joins DepYmed with over 22 years of pharmaceutical industry experience encompassing executive, scientific, operational and business development […]
Read More
DepYmed, Inc.

DepYmed, Inc. Announces $2 Million Financing

Completion of Series ‘A’ Round of Funding with TopSpin October 26, 2016 (Cold Spring Harbor, NY) – DepYmed, Inc., a pharmaceutical company focused on phosphatase inhibition for multiple therapeutic applications, today announced the completion of a Series ‘A’ Round of funding with TopSpin Fund, L.P. for a total of $2 million.  At closing, $1 million was […]
Read More